Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Pharmacogenomics--ready for prime time?

Shurin SB, Nabel EG.

N Engl J Med. 2008 Mar 6;358(10):1061-3. doi: 10.1056/NEJMe0800801. No abstract available.

PMID:
18322288
2.

Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.

Scott SA, Edelmann L, Kornreich R, Desnick RJ.

Am J Hum Genet. 2008 Feb;82(2):495-500. doi: 10.1016/j.ajhg.2007.10.002. Epub 2008 Jan 17.

3.

CYP4F2 genetic variant alters required warfarin dose.

Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, Hubbard J, Turpaz Y, Langaee TY, Eby C, King CR, Brower A, Schmelzer JR, Glurich I, Vidaillet HJ, Yale SH, Qi Zhang K, Berg RL, Burmester JK.

Blood. 2008 Apr 15;111(8):4106-12. doi: 10.1182/blood-2007-11-122010. Epub 2008 Feb 4.

4.

Use of genetic and nongenetic factors in warfarin dosing algorithms.

Wu AH.

Pharmacogenomics. 2007 Jul;8(7):851-61. doi: 10.2217/14622416.8.7.851. Review.

PMID:
18240910
5.

Genetic testing for warfarin dosing? Not yet ready for prime time.

Bussey HI, Wittkowsky AK, Hylek EM, Walker MB.

Pharmacotherapy. 2008 Feb;28(2):141-3. doi: 10.1592/phco.28.2.141. No abstract available.

PMID:
18225960
6.

Medication use leading to emergency department visits for adverse drug events in older adults.

Budnitz DS, Shehab N, Kegler SR, Richards CL.

Ann Intern Med. 2007 Dec 4;147(11):755-65.

PMID:
18056659
7.

Factors influencing warfarin dose requirements in African-Americans.

Momary KM, Shapiro NL, Viana MA, Nutescu EA, Helgason CM, Cavallari LH.

Pharmacogenomics. 2007 Nov;8(11):1535-44.

PMID:
18034618
8.

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.

Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, Kahn SF, May HT, Samuelson KM, Muhlestein JB, Carlquist JF; Couma-Gen Investigators.

Circulation. 2007 Nov 27;116(22):2563-70. Epub 2007 Nov 7.

9.

CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.

Caraco Y, Blotnick S, Muszkat M.

Clin Pharmacol Ther. 2008 Mar;83(3):460-70. Epub 2007 Sep 12.

PMID:
17851566
10.

Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action.

Wysowski DK, Nourjah P, Swartz L.

Arch Intern Med. 2007 Jul 9;167(13):1414-9.

PMID:
17620536
11.

Evaluation of genetic factors for warfarin dose prediction.

Caldwell MD, Berg RL, Zhang KQ, Glurich I, Schmelzer JR, Yale SH, Vidaillet HJ, Burmester JK.

Clin Med Res. 2007 Mar;5(1):8-16. Erratum in: Clin Med Res. 2007 Jun;5(2):142.

12.

Genetic-based dosing in orthopedic patients beginning warfarin therapy.

Millican EA, Lenzini PA, Milligan PE, Grosso L, Eby C, Deych E, Grice G, Clohisy JC, Barrack RL, Burnett RS, Voora D, Gatchel S, Tiemeier A, Gage BF.

Blood. 2007 Sep 1;110(5):1511-5. Epub 2007 Mar 26.

13.

Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians.

Schelleman H, Chen Z, Kealey C, Whitehead AS, Christie J, Price M, Brensinger CM, Newcomb CW, Thorn CF, Samaha FF, Kimmel SE.

Clin Pharmacol Ther. 2007 May;81(5):742-7. Epub 2007 Feb 28.

PMID:
17329985
14.

Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans.

Kimmel SE, Christie J, Kealey C, Chen Z, Price M, Thorn CF, Brensinger CM, Newcomb CW, Whitehead AS.

Pharmacogenomics J. 2008 Feb;8(1):53-60. Epub 2007 Feb 27.

PMID:
17325732
15.

A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance.

Loebstein R, Dvoskin I, Halkin H, Vecsler M, Lubetsky A, Rechavi G, Amariglio N, Cohen Y, Ken-Dror G, Almog S, Gak E.

Blood. 2007 Mar 15;109(6):2477-80. Epub 2006 Nov 16.

16.

Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.

Kimura R, Miyashita K, Kokubo Y, Akaiwa Y, Otsubo R, Nagatsuka K, Otsuki T, Okayama A, Minematsu K, Naritomi H, Honda S, Tomoike H, Miyata T.

Thromb Res. 2007;120(2):181-6. Epub 2006 Oct 17.

PMID:
17049586
17.

Association of warfarin dose with genes involved in its action and metabolism.

Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C, Bentley D, McGinnis R, Deloukas P.

Hum Genet. 2007 Mar;121(1):23-34. Epub 2006 Oct 18.

18.

A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9.

Tham LS, Goh BC, Nafziger A, Guo JY, Wang LZ, Soong R, Lee SC.

Clin Pharmacol Ther. 2006 Oct;80(4):346-55.

PMID:
17015052
19.

APOE genotype makes a small contribution to warfarin dose requirements.

Sconce EA, Daly AK, Khan TI, Wynne HA, Kamali F.

Pharmacogenet Genomics. 2006 Aug;16(8):609-11.

PMID:
16847429
20.

Supplemental Content

Support Center